ARGENX SE - ADR (ARGX) Stock News
NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR
ARGX Latest News and Analysis
argenx Highlights 2025 Strategic Priorities
argenx Highlights 2025 Strategic Priorities
Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA...
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio...
argenx to Present at Upcoming Investor Conferences
argenx to Present at Upcoming Investor Conferences
November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under...
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am...
argenx to Participate at Upcoming Investor Conferences
argenx to Participate at Upcoming Investor Conferences
November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China,...
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of...
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated...